胆汁酸与肠道菌群在原发性胆汁性胆管炎发生发展中的作用及机制

吴梦瑶; 潘佳茵; 丁瑢; 李劲榆; 邰文琳

doi:10.12449/JCH260427

胆汁酸与肠道菌群在原发性胆汁性胆管炎发生发展中的作用及机制

DOI: 10.12449/JCH260427

昆明医科大学第二附属医院检验科，昆明 650101

基金项目:

国家自然科学基金 (82060385);

国家自然科学基金 (82560413);

云南省基础研究计划昆医联合专项面上项目 (202201AY070001-099)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：吴梦瑶负责文章的构思和论文撰写；潘佳茵、丁瑢负责论文框架的构建；李劲榆负责指导撰写文章；邰文琳负责最终版本修订，对论文整体负责。

详细信息

通信作者:
邰文琳， taiwenlin@kmmu.edu.cn （ORCID： 0000-0002-8278-929X）

计量
- 文章访问数: 13
- HTML全文浏览量: 2
- PDF下载量: 0
- 被引次数: 0
出版历程
- 收稿日期: 2025-06-21
- 录用日期: 2025-10-27
- 出版日期: 2026-04-25

Roles and mechanism of bile acids and gut microbiota in primary biliary cholangitis

Department of Laboratory Medicine，The Second Affiliated Hospital of Kunming Medical University，Kunming 650101，China

Research funding:

National Natural Science Foundation of China (82060385);

National Natural Science Foundation of China (82560413);

General Project of the Joint Special Program between Kunming Medical University and Yunnan Provincial Basic Research Plan (202201AY070001-099)

More Information

Corresponding author: TAI Wenlin， taiwenlin@kmmu.edu.cn （ORCID： 0000-0002-8278-929X）

摘要

摘要: 原发性胆汁性胆管炎（PBC）是一种以肝内小胆管损伤为特征的胆汁淤积性自身免疫性肝病，其确切发病机制尚未完全阐明。近年来研究表明，胆汁酸代谢紊乱与肠道菌群失衡在PBC的发生与进展中扮演关键角色，二者通过“肠-肝轴”形成复杂的动态互作网络，协同调控免疫应答、代谢稳态以及炎症反应等核心生理病理过程。本文系统阐述了PBC中胆汁酸代谢与肠道菌群的异常特征，深入探讨其在PBC中的协同作用机制，并在此基础上提出联合靶向胆汁酸受体与调节肠道菌群的策略，有望突破现有治疗手段的局限，为PBC的临床干预提供新的思路与方向。
- 原发性胆汁性胆管炎 /
- 胆汁酸类和盐类 /
- 胃肠道微生物组
Abstract: Primary biliary cholangitis （PBC） is a cholestatic autoimmune liver disease characterized by the injury of small intrahepatic bile ducts， and at present， the pathogenesis of PBC remains unclear. Recent studies have shown that bile acid metabolism disorder and gut microbiota imbalance play a key role in the development and progression of PBC， and they form a complex and dynamic interaction network via the “gut-liver axis” and regulate core physiopathological processes such as immune response， metabolic homeostasis， and inflammatory response in a synergistic manner. This article systematically elaborates on the abnormal features of bile acid metabolism and gut microbiota in PBC， discusses their synergistic mechanisms in PBC， and then proposes a combined strategy of targeting bile acid receptors and modulating gut microbiota， in order to overcome the limitations of current treatment modalities and provide new insights and directions for the clinical management of PBC.
- Primary Biliary Cholangitis /
- Bile Acids and Salts /
- Gastrointestinal Microbiome

HTML全文

注： MDSC，髓源性抑制细胞；CX3CL1，趋化因子CX3C配体1；REG3γ，再生胰岛衍生蛋白3γ；PDC-E2，线粒体丙酮酸脱氢酶复合体E2亚单位。

图 1 “肠-肝轴”在PBC发生发展中的作用机制

Figure 1. Mechanism of the gut-liver axis in the development of PBC

下载: 全尺寸图片幻灯片

参考文献(56)

[1]	CHEN S, DUAN WJ, YOU H, et al. Recommendations of APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis[J]. Chin J Hepatol, 2022, 30( 2): 196- 198. DOI: 10.3760/cma.j.cn501113-20220208-00058. 陈莎, 段维佳, 尤红, 等. 亚太肝病学会«原发性胆汁性胆管炎临床诊疗指南»推荐意见[J]. 中华肝脏病杂志, 2022, 30( 2): 196- 198. DOI: 10.3760/cma.j.cn501113-20220208-00058.
[2]	National Health Commission of the People's Republic of China. Guidelines for the diagnosis and treatment of primary biliary cholangitis(2025 edition)[J]. J Clin Hepatol, 2025, 41( 8): 1504- 1506. DOI: 10.12449/JCH250805. 中华人民共和国国家卫生健康委员会. 原发性胆汁性胆管炎诊疗指南(2025年版)[J]. 临床肝胆病杂志, 2025, 41( 8): 1504- 1506. DOI: 10.12449/JCH250805.
[3]	SUN DY, XIE CP, ZHAO Y, et al. The gut microbiota-bile acid axis in cholestatic liver disease[J]. Mol Med, 2024, 30( 1): 104. DOI: 10.1186/s10020-024-00830-x.
[4]	QIAN QW, HE W, TANG RQ, et al. Implications of gut microbiota in autoimmune liver diseases[J]. Minerva Gastroenterol, 2023, 69( 1): 95- 106. DOI: 10.23736/s2724-5985.21.02860-9.
[5]	LIWINSKI T, HEINEMANN M, SCHRAMM C. The intestinal and biliary microbiome in autoimmune liver disease-current evidence and concepts[J]. Semin Immunopathol, 2022, 44( 4): 485- 507. DOI: 10.1007/s00281-022-00936-6.
[6]	CHEN S. Research of namonaphene-NAD⁺ regulates cholestasis through SIRT1/PGC-1α/TFAM pathway[D]. Chongqing: Chongqing Medical University, 2022. DOI: 10.27674/d.cnki.gcyku.2022.001356. 陈思. 纳米NAD⁺通过SIRT1/PGC-1α/TFAM通路治疗胆汁淤积的研究[D]. 重庆: 重庆医科大学, 2022. DOI: 10.27674/d.cnki.gcyku.2022.001356.
[7]	BAO J, ZHANG X, YE M, et al. Exploration of novel metabolic mechanisms underlying primary biliary cholangitis using hepatic metabolomics, lipidomics, and proteomics analysis[J]. J Proteome Res, 2025, 24( 2): 562- 578. DOI: 10.1021/acs.jproteome.4c00708.
[8]	CHEN WH, WEI YR, XIONG AZ, et al. Comprehensive analysis of serum and fecal bile acid profiles and interaction with gut microbiota in primary biliary cholangitis[J]. Clin Rev Allergy Immunol, 2020, 58( 1): 25- 38. DOI: 10.1007/s12016-019-08731-2.
[9]	MEDINA J. Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis[J]. Hepatology, 1997, 25( 1): 12- 17. DOI: 10.1053/jhep.1997.v25.pm0008985258.
[10]	CHE Y, XU WF, DING CJ, et al. Bile acids target mitofusin 2 to differentially regulate innate immunity in physiological versus cholestatic conditions[J]. Cell Rep, 2023, 42( 1): 112011. DOI: 10.1016/j.celrep.2023.112011.
[11]	SASAKI M, MIYAKOSHI M, SATO Y, et al. Modulation of the microenvironment by senescent biliary epithelial cells may be involved in the pathogenesis of primary biliary cirrhosis[J]. J Hepatol, 2010, 53( 2): 318- 325. DOI: 10.1016/j.jhep.2010.03.008.
[12]	GAO Y, SHEN XX, XIA SQ, et al. Bile acid composition and their impact of response to immunosuppressant or UCDA therapy in patients with autoimmune hepatitis and primary biliary cholangitis[J]. J Pract Hepatol, 2024, 27( 5): 709- 712. DOI: 10.3969/j.issn.1672-5069.2024.05.016. 高怡, 沈小雪, 夏素芹, 等. 自身免疫性肝炎和原发性胆汁性胆管炎患者血清胆汁酸成分变化及其对治疗应答的影响[J]. 实用肝脏病杂志, 2024, 27( 5): 709- 712. DOI: 10.3969/j.issn.1672-5069.2024.05.016.
[13]	MARTINEZ-GILI L, PECHLIVANIS A, MCDONALD JAK, et al. Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitis[J]. Gut Microbes, 2023, 15( 1): 2208501. DOI: 10.1080/19490976.2023.2208501.
[14]	BYUN S, KIM DH, RYERSON D, et al. Postprandial FGF19-induced phosphorylation by Src is critical for FXR function in bile acid homeostasis[J]. Nat Commun, 2018, 9( 1): 2590. DOI: 10.1038/s41467-018-04697-5.
[15]	JUNG H, CHEN JJ, HU XM, et al. BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination[J]. JCI Insight, 2020, 6( 1): e141640. DOI: 10.1172/jci.insight.141640.
[16]	WUNSCH E, MILKIEWICZ M, WASIK U, et al. Expression of hepatic fibroblast growth factor 19 is enhanced in primary biliary cirrhosis and correlates with severity of the disease[J]. Sci Rep, 2015, 5: 13462. DOI: 10.1038/srep13462.
[17]	BOYER JL, TRAUNER M, MENNONE A, et al. Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTα-OSTβ in cholestasis in humans and rodents[J]. Am J Physiol Gastrointest Liver Physiol, 2006, 290( 6): G1124- G1130. DOI: 10.1152/ajpgi.00539.2005.
[18]	TAKEYAMA Y, KANEGAE K, INOMATA S, et al. Sustained upregulation of sodium taurocholate cotransporting polypeptide and bile salt export pump and downregulation of cholesterol 7α-hydroxylase in the liver of patients with end-stage primary biliary cirrhosis[J]. Med Mol Morphol, 2010, 43( 3): 134- 138. DOI: 10.1007/s00795-009-0480-9.
[19]	BIDAULT-JOURDAINNE V, MERLEN G, GLÉNISSON M, et al. TGR5 controls bile acid composition and gallbladder function to protect the liver from bile acid overload[J]. JHEP Rep, 2021, 3( 2): 100214. DOI: 10.1016/j.jhepr.2020.100214.
[20]	HUANG D, ZHAO YY, WANG RM, et al. Natural product-based screening led to the discovery of a novel PXR agonist with anti-cholestasis activity[J]. Acta Pharmacol Sin, 2022, 43( 8): 2139- 2146. DOI: 10.1038/s41401-021-00793-3.
[21]	van DIJK R, KREMER AE, SMIT W, et al. Characterization and treatment of persistent hepatocellular secretory failure[J]. Liver Int, 2015, 35( 4): 1478- 1488. DOI: 10.1111/liv.12603.
[22]	KOWDLEY KV, BOWLUS CL, LEVY C, et al. Efficacy and safety of elafibranor in primary biliary cholangitis[J]. N Engl J Med, 2024, 390( 9): 795- 805. DOI: 10.1056/NEJMoa2306185.
[23]	HIRSCHFIELD GM, BOWLUS CL, MAYO MJ, et al. A phase 3 trial of seladelpar in primary biliary cholangitis[J]. N Engl J Med, 2024, 390( 9): 783- 794. DOI: 10.1056/NEJMoa2312100.
[24]	KEMPINSKA-PODHORODECKA A, MILKIEWICZ M, WASIK U, et al. Decreased expression of vitamin D receptor affects an immune response in primary biliary cholangitis via the VDR-miRNA155-SOCS1 pathway[J]. Int J Mol Sci, 2017, 18( 2): 289. DOI: 10.3390/ijms18020289.
[25]	SONG LT, HOU YS, XU D, et al. Hepatic FXR-FGF4 is required for bile acid homeostasis via an FGFR4-LRH-1 signal node under cholestatic stress[J]. Cell Metab, 2025, 37( 1): 104- 120. DOI: 10.1016/j.cmet.2024.09.008.
[26]	KHO ZY, LAL SK. The human gut microbiome- a potential controller of wellness and disease[J]. Front Microbiol, 2018, 9: 1835. DOI: 10.3389/fmicb.2018.01835.
[27]	JIANG HY, YU Y, HU XX, et al. The fecal microbiota of patients with primary biliary cholangitis(PBC) causes PBC-like liver lesions in mice and exacerbates liver damage in a mouse model of PBC[J]. Gut Microbes, 2024, 16( 1): 2383353. DOI: 10.1080/19490976.2024.2383353.
[28]	LV LX, FANG DQ, SHI D, et al. Alterations and correlations of the gut microbiome, metabolism and immunity in patients with primary biliary cirrhosis[J]. Environ Microbiol, 2016, 18( 7): 2272- 2286. DOI: 10.1111/1462-2920.13401.
[29]	MA HD, ZHAO ZB, MA WT, et al. Gut microbiota translocation promotes autoimmune cholangitis[J]. J Autoimmun, 2018, 95: 47- 57. DOI: 10.1016/j.jaut.2018.09.010.
[30]	TANG RQ, WEI YR, LI YM, et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy[J]. Gut, 2018, 67( 3): 534- 541. DOI: 10.1136/gutjnl-2016-313332.
[31]	KITAHATA S, YAMAMOTO Y, YOSHIDA O, et al. Ileal mucosa-associated microbiota overgrowth associated with pathogenesis of primary biliary cholangitis[J]. Sci Rep, 2021, 11( 1): 19705. DOI: 10.1038/s41598-021-99314-9.
[32]	LUO X, YOU X. Genetic predisposition of the gastrointestinal microbiome and primary biliary cholangitis: A bi-directional, two-sample Mendelian randomization analysis[J]. Front Endocrinol, 2023, 14: 1225742. DOI: 10.3389/fendo.2023.1225742.
[33]	ZHOU ZJ, LI WX, WU YL, et al. Bidirectional Mendelian randomization links gut microbiota to primary biliary cholangitis[J]. Sci Rep, 2024, 14( 1): 28301. DOI: 10.1038/s41598-024-79227-z.
[34]	CAI J, SUN LL, GONZALEZ FJ. Gut microbiota-derived bile acids in intestinal immunity, inflammation, and tumorigenesis[J]. Cell Host Microbe, 2022, 30( 3): 289- 300. DOI: 10.1016/j.chom.2022.02.004.
[35]	SANO T, HUANG W, HALL JA, et al. An IL-23R/IL-22 circuit regulates epithelial serum amyloid a to promote local effector Th17 responses[J]. Cell, 2015, 163( 2): 381- 393. DOI: 10.1016/j.cell.2015.08.061.
[36]	HARADA K, SHIMODA S, SATO Y, et al. Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis[J]. Clin Exp Immunol, 2009, 157( 2): 261- 270. DOI: 10.1111/j.1365-2249.2009.03947.x.
[37]	LIU M, JI YL, HU YJ, et al. Lactococcus garvieae aggravates cholestatic liver disease by increasing intestinal permeability and enhancing bile acid reabsorption[J]. World J Gastroenterol, 2025, 31( 10): 101014. DOI: 10.3748/wjg.v31.i10.101014.
[38]	LEMOINNE S, SABINO J, SOKOL H. Gut microbiota in PSC: From association to possible causality. Commentary to"Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis" by Nakamoto et al. Nature Microbiology, January 2019[J]. Clin Res Hepatol Gastroenterol, 2020, 44( 2): 123- 125. DOI: 10.1016/j.clinre.2019.06.005.
[39]	GULAMHUSEIN AF, HIRSCHFIELD GM. Primary biliary cholangitis: Pathogenesis and therapeutic opportunities[J]. Nat Rev Gastroenterol Hepatol, 2020, 17( 2): 93- 110. DOI: 10.1038/s41575-019-0226-7.
[40]	ZHAO JM, ZHAO SX, ZHOU GD, et al. Altered biliary epithelial cell and monocyte responses to lipopolysaccharide as a TLR ligand in patients with primary biliary cirrhosis[J]. Scand J Gastroenterol, 2011, 46( 4): 485- 494. DOI: 10.3109/00365521.2010.539624.
[41]	WANG AP, MIGITA K, ITO M, et al. Hepatic expression of toll-like receptor 4 in primary biliary cirrhosis[J]. J Autoimmun, 2005, 25( 1): 85- 91. DOI: 10.1016/j.jaut.2005.05.003.
[42]	MAO TK, LIAN ZX, SELMI C, et al. Altered monocyte responses to defined TLR ligands in patients with primary biliary cirrhosis[J]. Hepatology, 2005, 42( 4): 802- 808. DOI: 10.1002/hep.20859.
[43]	LIU ZY, ZHANG JN, YANG XL, et al. High-throughput sequencing reveals the characteristics of T cell receptor profiles in patients with primary biliary cholangitis[J/CD]. Chin J Liver Dis(Electronic Version), 2024, 16( 1): 38- 44. DOI: 10.3969/j.issn.1674-7380.2024.01.007. 刘珍玉, 张俊宁, 杨雪丽, 等. 高通量测序揭示原发性胆汁性胆管炎患者的T细胞受体图谱特征[J/CD]. 中国肝脏病杂志(电子版), 2024, 16( 1): 38- 44. DOI: 10.3969/j.issn.1674-7380.2024.01.007.
[44]	YANG Y, CHOI J, CHEN Y, et al. E. coli and the etiology of human PBC: Antimitochondrial antibodies and spreading determinants[J]. Hepatology, 2022, 75( 2): 266- 279. DOI: 10.1002/hep.32172.
[45]	TANAKA A, LEUNG PSC, GERSHWIN ME. Pathogen infections and primary biliary cholangitis[J]. Clin Exp Immunol, 2019, 195( 1): 25- 34. DOI: 10.1111/cei.13198.
[46]	TAKAHASHI D, HOSHINA N, KABUMOTO Y, et al. Microbiota-derived butyrate limits the autoimmune response by promoting the differentiation of follicular regulatory T cells[J]. EBioMedicine, 2020, 58: 102913. DOI: 10.1016/j.ebiom.2020.102913.
[47]	WANG R, LI B, HUANG BY, et al. Gut microbiota-derived butyrate induces epigenetic and metabolic reprogramming in myeloid-derived suppressor cells to alleviate primary biliary cholangitis[J]. Gastroenterology, 2024, 167( 4): 733- 749. DOI: 10.1053/j.gastro.2024.05.014.
[48]	ZHANG L, YANG L, CHU HK. Targeting gut microbiota for the treatment of primary biliary cholangitis: From bench to bedside[J]. J Clin Transl Hepatol, 2023, 11( 4): 958- 966. DOI: 10.14218/JCTH.2022.00408.
[49]	LIU QY, HUANG BY, ZHOU YJ, et al. Gut microbiome pattern impacts treatment response in primary biliary cholangitis[J]. Med, 2025, 6( 1): 100504. DOI: 10.1016/j.medj.2024.08.003.
[50]	LIU YH, CHEN KF, LI FY, et al. Probiotic Lactobacillus rhamnosus GG prevents liver fibrosis through inhibiting hepatic bile acid synthesis and enhancing bile acid excretion in mice[J]. Hepatology, 2020, 71( 6): 2050- 2066. DOI: 10.1002/hep.30975.
[51]	LI B, ZHANG J, CHEN Y, et al. Alterations in microbiota and their metabolites are associated with beneficial effects of bile acid sequestrant on icteric primary biliary cholangitis[J]. Gut Microbes, 2021, 13( 1): 1946366. DOI: 10.1080/19490976.2021.1946366.
[52]	LI DP, WAN MJ, XUE LF, et al. Zinc promotes microbial p-coumaric acid production that protects against cholestatic liver injury[J]. Cell Host Microbe, 2024, 32( 12): 2195- 2211. DOI: 10.1016/j.chom.2024.11.002.
[53]	REICHARDT F, LUCAS LN, OKYERE L, et al. Portal bile acid composition and microbiota along the murine intestinal tract exhibit sex differences in physiology[J]. Gut Microbes, 2025, 17( 1): 2540483. DOI: 10.1080/19490976.2025.2540483.
[54]	WATANABE M, FUKIYA S, YOKOTA A. Comprehensive evaluation of the bactericidal activities of free bile acids in the large intestine of humans and rodents[J]. J Lipid Res, 2017, 58( 6): 1143- 1152. DOI: 10.1194/jlr.M075143.
[55]	WAHLSTRÖM A, SAYIN SI, MARSCHALL HU, et al. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism[J]. Cell Metab, 2016, 24( 1): 41- 50. DOI: 10.1016/j.cmet.2016.05.005.
[56]	WEINGARDEN AR, CHEN C, BOBR A, et al. Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection[J]. Am J Physiol Gastrointest Liver Physiol, 2014, 306( 4): G310- G319. DOI: 10.1152/ajpgi.00282.2013.